✦ LIBER ✦

Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

✍ Scribed by Amrita Krishnan; Marcelo C Pasquini; Brent Logan; Edward A Stadtmauer; David H Vesole; Edwin Alyea 3rd; Joseph H Antin; Raymond Comenzo; Stacey Goodman; Parameswaran Hari; Ginna Laport; Muzaffar H Qazilbash; Scott Rowley; Firoozeh Sahebi; George Somlo; Dan T Vogl; Daniel Weisdorf; Marian Ewell; Juan Wu; Nancy L Geller; Mary M Horowitz; Sergio Giralt; David G Maloney

Book ID: 117785783
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 272 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70243-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose chemotherapy plus autologous s

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

✍ Cook, Gordon; Williams, Cathy; Brown, Julia M; Cairns, David A; Cavenagh, Jamie; 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 335 KB

A Phase II Trial of Autologous Stem Cell

A Phase II Trial of Autologous Stem Cell Transplantation Followed by Mini-Allogeneic Stem Cell Transplantation for the Treatment of Multiple Myeloma: An Analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97

✍ David H. Vesole; Lijun Zhang; Neal Flomenberg; Philip R. Greipp; Hillard M. Laza 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 235 KB

Phase II Trial of Intravenously Administ

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide Based Initial Therapy

✍ S. Kumar; J. Mikhael; M. Lacy; B. LaPlant; F. Buadi; D. Dingli; M. Gertz; T. Mic 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Induction therapy with vincristine, adri

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma

✍ Lokhorst, H M; Sonneveld, P; Cornelissen, J J; Joosten, P; van Marwijk Kooy, M; 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 66 KB

A Phase I Dose-Escalation Trial of High-

A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

✍ Abidi, Muneer H.; Agarwal, Rishi; Tageja, Nishant; Ayash, Lois; Deol, Abhinav; A 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 152 KB

A Randomized Phase II Trial of Fludarabi

A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

✍ Bashir, Qaiser; Khan, Hassan; Thall, Peter F.; Liu, Ping; Shah, Nina; Kebriaei, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 278 KB